๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Yantai
Clinical trial register · China

Clinical Trials in Yantai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Yantai

27 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
A Trial to Explore the Efficacy and Safety of O-triple as Initial Therapy in the Active Lupus Nephritis Patients (INITIAL Trial)
NCT07767188Lupus Nephritis
Zhao Minghui
Phase 3
70
Fuzhou, Guangzhou, Harbin, Nanjing, Xuzhou, Nanchang, Shenyang, Yantai
2026-09-10
Not yet open
TEAS Timing for Gastrectomy Recovery (TEAS-TIME Trial)
NCT07714980Gastric Cancer (GC), Stomach Neoplasms
The Affiliated Hospital of Qingdao University
Not applicable
300
Dongying, Qingdao, Rizhao, Weifang, Weihai, Yantai
2026-07
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Novartis Pharmaceuticals
Phase 3
460
Hefei, Guangzhou, Wuhan, Nanjing, Nantong, Changchun, Jinan, Yantai
2026-06-16
Recruiting
Chinese Adults With Kidney Disease
NCT07522099Immunoglobulin A Nephropathy (IgAN), Complement 3 Glomerulopathy (C3G), IC-MPGN
ADARx Pharmaceuticals, Inc.
Phase 2
30
Shenzhen, Guiyang, Zhengzhou, Baotou, Wuxi, Yantai, Beijing, Shandong
2026-05-21
Not yet open
A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer
NCT07485920Limited-stage Small Cell Lung Cancer (LS-SCLC)
The Affiliated Hospital of Qingdao University
Phase 4
20
Qingdao, Weihai, Yantai, Zibo
2026-05-01
Recruiting
A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) With or Without Comorbid Asthma
NCT07436949Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Bambusa Therapeutics
Phase 1/2
64
Beijing, Guangzhou, Changsha, Nanjing, Jinan, Qingdao, Yantai, Zibo
2026-03-02
Not yet open
Efficacy of S.T.O.PยฎKIT in Retarding Axial Length Growth in Children With Low Hyperopia
NCT07401511Children, Hyperopia
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
180
Zhenzhou, Yantai, Shanghai
2026-02-01
By invitation
China-NINE Cohort๏ผšNeuroimmune Network in Elderly / Neurodegeneration
NCT07586501Cognitive Dysfunction, Cognitive Dysfunction, Cognitive Disorder, Parkinson's Disease (PD)
Yantai Yuhuangding Hospital
Observational
260
Yantai
2026-01-16
Recruiting
Effect of Predictive Model on Double-Balloon Enteroscopy
NCT07288346Double-balloon Enteroscopy
Shandong University
Not applicable
338
Dezhou, Qingdao, Yantai, Zaozhuang, Jinan
2026-01-12
Recruiting
A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC
NCT07815223SCLC, Limited Stage
Yantai Yuhuangding Hospital
Phase 2
20
Yantai
2025-11-04
Not yet open
A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Cancer (TNBC)
NCT07054242Neoadjuvant Therapy, Stage II to III (T1cN1-2 or T2-4N0-2) TNBC Breast Cancer
Yantai Yuhuangding Hospital
Phase 2
52
Yantai
2025-10-30
Recruiting
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
NCT07190196Immunoglobulin G4 Related Disease
Sanofi
Phase 3
124
Beijing, Chengdu, Hangzhou, Jiazhuang, Taiyuan, Wuhan, Yantai
2025-09-26
Active, closed
Lower Limb Biomechanics of the Roundhouse Kick in Elite and Youth Taekwondo Athletes Using FPCA
NCT07307378Taekwondo Roundhouse Kick Biomechanics
Universiti Sains Malaysia
Observational
52
Yantai
2025-09-01
Recruiting
A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
NCT07096843Primary Membranous Nephropathy
Climb Bio, Inc.
Phase 2
45
Beijing, Shenzhen, Wuxi, Xi'an, Jinan, Yantai, Yibin
2025-08-25
Recruiting
An Engineered Sirpฮฑ Fused to Anti-Pd-L1 And Tgf-ฮฒ Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors
NCT06487624Advanced Solid Tumor, Refractory Hodgkin Lymphoma
FBD Biologics Limited
Phase 1
50
Hangzhou, Xuzhou, Yantai, Zhujiang
2025-04-02
Active, closed
A Phase 2 in Adult Subjects With Hereditary Angioedema
NCT06846398Hereditary Angioedema (HAE)
Shanghai Argo Biopharmaceutical Co., Ltd.
Phase 2
25
Beijing, Lanzhou, Wuhan, Yantai, Chengdu, Kunming
2025-02-28
Active, closed
Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer
NCT06693128Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Ruijin Hospital
Phase 2
80
Chengdu, Shanghai, Yantai
2024-11-21
Active, closed
Volrustomig Priming Regimens Exploratory Phase II Platform Study
NCT06448754Non-small Cell Lung Cancer
AstraZeneca
Phase 2
194
Beijing, Hangzhou, Jinan, Yantai, Zhengzhou
2024-08-27
Recruiting
Tirofiban for Patients With intraCranial Artery Stenosis and High-risk Acute Non-disabling Cerebrovascular Events(CHANCE-4๏ผ‰
NCT06319846Ischemic Stroke, Acute, TIA, Symptomatic Intracranial Artery Stenosis
Beijing Tiantan Hospital
Phase 3
4,674
Harbin, Dezhou, Liaocheng, Yantai
2024-07-11
Active, closed
Postoperative Adjuvant Therapy for Stage II-III Gastric Cancer
NCT06609759Stage II-III Gastric Cancer
Qilu Hospital of Shandong University
Observational
197
Jinan, Qingdao, Yantai
2024-01-01
Recruiting
PPG vs. ICG in Gastrointestinal Resections
NCT06222645Anastomosis, Perfusion, Postoperative Complications, Gastrointestinal Neoplasms
Saint Petersburg State University, Russia
Not applicable
200
Yantai
2023-11-01
Active, closed
Minimal Residual Disease-guided Adjuvant Therapy for Gastric Cancer
NCT06157216Stage II-III Gastric Cancer
Qilu Hospital of Shandong University
Not applicable
65
Jinan, Qingdao, Yantai
2023-10-01
Recruiting
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
NCT05981703Advanced Solid Tumor, Solid Tumor
BeOne Medicines
Phase 1
337
Hefei, Harbin, Wuhan, Shenyang, Jining, Yantai, Shanghai, Chengdu
2023-09-21
Active, closed
Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy
NCT05585580Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Qilu Hospital of Shandong University
Phase 2
59
Jinan, Qingdao, Yantai, Linyi
2023-03-01
Active, closed
First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer
NCT05586061HER2-positive Gastric Cancer
Qilu Hospital of Shandong University
Phase 2
55
Jinan, Qingdao, Yantai
2023-02-10
Active, closed
A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease
NCT05662241IgG4 Related Disease
Zenas BioPharma (USA), LLC
Phase 3
194
Beijing, Shijiazhuang, Wuhai, Yantai, Shanghai, Taiyuan, Chengdu
2023-01-09
Recruiting
Percutaneous Electrocoagulation Versus Sclerosing Foam for Patients With Incompetent Perforating Veins
NCT04686097Incompetent Perforating Veins
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
84
Hefei, Yantai, Shanghai, Hangzhou
2021-01-01
Rows per page Showing 1–27 of 27
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/yantai

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 27 of those studies with a site in Yantai.

How many clinical trials are recruiting in Yantai?

12 of the 27 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 5 have not yet opened recruitment, 9 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Yantai), 27 studies
PhaseStudiesRecruitingShare
Phase 29333.3%
Not applicable6322.2%
Phase 35318.5%
Observational3011.1%
Phase 1227.4%
Phase 1/2113.7%
Phase 4103.7%

Most active sponsors

Lead sponsors with the most studies (Yantai)
Lead sponsorStudiesRecruiting
Qilu Hospital of Shandong University40
Yantai Yuhuangding Hospital31
The Affiliated Hospital of Qingdao University20
ADARx Pharmaceuticals, Inc.11
AstraZeneca10
Bambusa Therapeutics11
Beijing Tiantan Hospital11
BeOne Medicines11
Climb Bio, Inc.11
FBD Biologics Limited11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.